Overcoming Acquired MET-Driven Resistance to First-Line Lorlatinib: Successful Combination of Lorlatinib and Envafolimab in an ALK-Positive NSCLC Patient with Ultra-High PD-L1 Expression.
Saved in:
| Title: | Overcoming Acquired MET-Driven Resistance to First-Line Lorlatinib: Successful Combination of Lorlatinib and Envafolimab in an ALK-Positive NSCLC Patient with Ultra-High PD-L1 Expression. |
|---|---|
| Authors: | Ding, Lu1 (AUTHOR), Nuersulitan, Reyizha1 (AUTHOR), Wang, Jingjing1 (AUTHOR), Chen, Hanxiao1 (AUTHOR), Zhuo, Minglei1 (AUTHOR) zhuominglei@bjmu.edu.cn |
| Source: | Current Oncology. May2026, Vol. 33 Issue 5, p258. 10p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
